25N-NBOMe

Hypertension, Arrhythmia, Prior cardiac events, Long QT syndrome, Heart failure

Tachycardia, hypertension, and possible QT prolongation from sympathomimetic and serotonergic activation create risk of acute cardiovascular decompensation in susceptible individuals. QT prolongation documented in rat ECG studies for 25D-NBOMe and 25C-NBOMe.

Concurrent cocaine use, Concurrent amphetamine use

Co-administration of stimulants with 25N-NBOMe produces additive sympathomimetic effects — tachycardia, hypertension, hyperthermia, and vasoconstriction — risking hypertensive crisis, cardiac arrhythmia, and seizures. Cocaine listed as 'dangerous' in seed interaction data.

Epilepsy, Lowered seizure threshold

Seizures are a documented feature of severe NBOMe intoxication across the class. Individuals with pre-existing seizure disorders face compounded risk from 25N-NBOMe's seizure-threshold-reducing properties.

Schizophrenia, Schizoaffective disorder

Potent 5-HT₂A agonism carries established risk of psychosis precipitation in individuals with psychotic spectrum disorders. The NBOMe class's steep dose-response and prominent anxiogenic profile further elevate this risk.

Bipolar I, Bipolar II

Potent serotonergic psychedelics carry risk of precipitating manic episodes and destabilizing mood in individuals with bipolar disorder.

Fluconazole, Fluvoxamine, Omeprazole

CYP2C9 and CYP2C19 mediate O-demethylation of NBOMe compounds (Caspar et al. 2015, 25I-NBOMe). Inhibitors of these enzymes could reduce metabolic clearance of 25N-NBOMe, increasing plasma concentrations and elevating toxicity risk. No formal drug–drug interaction study has been conducted.

Pregnancy, Breastfeeding

No data on reproductive or developmental toxicity for 25N-NBOMe or any NBOMe compound. Precautionary absolute contraindication based on the compound's potent serotonergic and sympathomimetic pharmacological activity.

Concurrent MAOI therapy, Recent MAOI use within washout period

MAOIs prevent serotonin degradation; co-administration with a potent 5-HT₂A full agonist dramatically increases serotonin syndrome risk. Serotonin syndrome documented for NBOMe compounds in systematic review (Schifano et al. 2021).

Concurrent SSRI therapy, Concurrent SNRI therapy

Co-administration with serotonergic antidepressants elevates serotonin syndrome risk. SSRIs may also attenuate psychedelic effects via 5-HT₂A receptor occupancy, leading to unpredictable dosing and potential compensatory redosing.

Concurrent tramadol use

Tramadol's serotonergic activity (5-HT and norepinephrine reuptake inhibition) compounds serotonin syndrome risk when combined with a potent 5-HT₂A agonist. Tramadol also lowers seizure threshold, compounding the intrinsic seizure risk of the NBOMe class.